IN THE NEWS

Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019

March 20th, 2019|

Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019 PALO ALTO, Calif., March 20, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and CEO, will present a corporate update at the China Healthcare Investment Conference (CHIC) at the Ritz-Carlton Shanghai Pudong Hotel in Shanghai, China on March 26 - 28. Eiger will host one-on-one meetings with [...]

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

March 14th, 2019|

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update Began 2019 with $100.4 million in cash, cash equivalents & short-term investmentsEnrollment of Phase 3 D-LIVR Study in HDV planned by end of 2019NDA and MAA filings for Progeria and Progeroid Laminopathies planned in 2019 PALO ALTO, Calif., March 14, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for [...]

Eiger Late-Breaker Oral Presentation of Peginterferon Lambda Phase 2 LIMT Study at The International Liver Congress™ 2019

March 13th, 2019|

Eiger Late-Breaker Oral Presentation of Peginterferon Lambda Phase 2 LIMT Study at The International Liver Congress™ 2019 36% Durable Virologic Response at 24 Weeks Post-Treatment PALO ALTO, Calif., March 13, 2019 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced a late-breaker oral presentation of Phase 2 LIMT HDV (Lambda Interferon MonoTherapy in Hepatitis Delta Virus) end of study 24 week post-treatment results will be presented at [...]